ENDECE will attend the 35th annual J.P. Morgan Healthcare Conference from January 9-12, 2017 in San Francisco, California. During the meeting, ENDECE will present an update on the clinical development of its lead compound, NDC-1308, a small molecule that induces remyelination, which is the restoration of the lost myelin sheath in patients suffering from multiple sclerosis (MS). NDC-1308 does this by up-regulating key genes required for oligodendrogenesis, the process by which oligodendrocyte progenitor cells (OPCs) differentiate into mature myelinating oligodendrocytes that can then repair the myelin sheath surrounding axons that have been damaged by MS.
ENDECE has assembled a library of proprietary compounds designed to stop disease by up-regulating specific biological pathways to stimulate a biological response for a gain of function. Phase 1 clinical studies of NDC-1308, the most advanced of those compounds, are slated to begin in late 2017. Stephen H. Nye, Ph.D., vice president of discovery at ENDECE, describes NDC-1308’s unique mechanism of action in this video interview with MedPage Today.
The J.P. Morgan Healthcare Conference is one of largest conferences in the life sciences industry. If you plan to attend conference, and would like to meet with ENDECE to discuss the company’s latest developments, please contact Jean Yarger at firstname.lastname@example.org.